IQVIA is trading at $257.29, a change of -4.29%, with no clear company-specific catalyst identified for the September 30 after-hours decline.

  • IQVIA’s third-quarter results are scheduled for October 27, not September 30.
  • UBS resumed coverage with a Buy rating and a $345 target, but its September 30 report does not explain the decline.
  • Major-index moves were mixed, and the available evidence does not establish a broad-market explanation.